Synapse - Saad Usmani

Results (296)

Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): Final analysis of griffin among clinically relevant subgroups

Meeting Abstract

Chari, A.; Kaufman, J. L.; Laubach, J. P.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
Blood (2022)

Fulltext@MSK | Save

Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world single center experience

Meeting Abstract

Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; Maclachlan, K. H.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C.; Akhlaghi, T.; more...
Blood (2022)

Fulltext@MSK | Save

The mutagenic impact of radiotherapy in multiple myeloma

Meeting Abstract

Diamond, B.; Poos, A. M.; Ziccheddu, B.; Maclachlan, K. H.; Zhang, Y.; Usmani, S.; Boyle, E. M.; Davies, F. E.; Morgan, G. J.; Landgren, O.; more...
Blood (2022)

Fulltext@MSK | Save

A randomized placebo controlled study of a plant-based dietary versus supplement versus placebo intervention in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) study

Meeting Abstract

Shah, U. A.; Castro, F.; Anuraj, A.; Schach, E.; Derkach, A.; Joseph, N. S.; Adintori, P. A.; Guttentag, L.; Blaslov, J.; Cross, J. R.; more...
Blood (2022)

Fulltext@MSK | Save

A pilot plant based dietary intervention in MGUS and SMM patients with elevated BMI is feasible and associated with improvements in metabolic and microbiome biomarkers of progression

Meeting Abstract

Shah, U. A.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Tran, L.; Adintori, P. A.; Burge, M.; Funkhouser, S.; Hosszu, K.; more...
Blood (2022)

Fulltext@MSK | Save

Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1

Meeting Abstract

Munshi, N. C.; Paiva, B.; Martin, T.; Usmani, S.; Lin, Y.; Schecter, J. M.; Jackson, C. C.; Madduri, D.; Zudaire, E.; Yeh, T. M.; more...
Blood (2022)

Fulltext@MSK | Save

A phase 2 trial of colesevelam for lenalidomide-associated diarrhea

Meeting Abstract

Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
Blood (2022)

Fulltext@MSK | Save

Teclistamab population pharmacokinetics and exposure-response relationship support 1.5 Mg/Kg dose regimen in relapsed/refractory multiple myeloma

Meeting Abstract

Miao, X.; Wu, L. S.; Wang Lin, S. X.; Xu, Y.; Chen, Y.; Iwaki, Y.; Kobos, R.; Stephenson, T.; Kemmerer, K.; Uhlar, C. M.; more...
Blood (2022)

Fulltext@MSK | Save

Stem cell mobilization characteristics for transplant eligible patients with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib, lenalidomide, dexamethasone, and daratumumab (KRd-Dara)